David P Tuck MD

Clinical Associate Professor, Hematology & Medical Oncology

820 Harrison Ave | (781) 491-4214

Hematology & Medical Oncology


MD, University of Vermont College of Medicine, 1985

Psychology, AB, Harvard College, 1974


Published on 8/24/2021

Erbe R, Wang Z, Wu S, Xiu J, Zaidi N, La J, Tuck D, Fillmore N, Giraldo NA, Topper M, Baylin S, Lippman M, Isaacs C, Basho R, Serebriiskii I, Lenz HJ, Astsaturov I, Marshall J, Taverna J, Lee J, Jaffee EM, Roussos Torres ET, Weeraratna A, Easwaran H, Fertig EJ. Evaluating the impact of age on immune checkpoint therapy biomarkers. Cell Rep. 2021 Aug 24; 36(8):109599. PMID: 34433020.

Published on 6/1/2021

Fillmore NR, La J, Szalat RE, Tuck DP, Nguyen V, Yildirim C, Do NV, Brophy MT, Munshi NC. Prevalence and Outcome of COVID-19 Infection in Cancer Patients: A National Veterans Affairs Study. J Natl Cancer Inst. 2021 06 01; 113(6):691-698. PMID: 33031532.

Published on 10/1/2020

La J, Cheng D, Brophy MT, Do NV, Lee JSH, Tuck D, Fillmore NR. Real-World Outcomes for Patients Treated With Immune Checkpoint Inhibitors in the Veterans Affairs System. JCO Clin Cancer Inform. 2020 10; 4:918-928. PMID: 33074743.

Published on 10/30/2019

Cheng D, Ramos-Cejudo J, Tuck D, Elbers D, Brophy M, Do N, Fillmore N. External validation of a prognostic model for mortality among patients with non-small-cell lung cancer using the Veterans Precision Oncology Data Commons. Semin Oncol. 2019 Aug - Oct; 46(4-5):327-333. PMID: 31708233.

Published on 10/2/2019

Do N, Grossman R, Feldman T, Fillmore N, Elbers D, Tuck D, Dhond R, Selva L, Meng F, Fitzsimons M, Ajjarapu S, Ayandeh S, Hall R, Do S, Brophy M. The Veterans Precision Oncology Data Commons: Transforming VA data into a national resource for research in precision oncology. Semin Oncol. 2019 Aug - Oct; 46(4-5):314-320. PMID: 31629530.

Published on 8/31/2017

Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, Parker J, Hafeez A, Tuck D, Younes A. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017 11; 102(11):1923-1930. PMID: 28860342.

Published on 6/20/2017

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS. New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016. J Immunother Cancer. 2017; 5:50. PMID: 28649381.

Published on 12/15/2016

Sun K, Atoyan R, Borek MA, Dellarocca S, Samson ME, Ma AW, Xu GX, Patterson T, Tuck DP, Viner JL, Fattaey A, Wang J. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers. Mol Cancer Ther. 2017 02; 16(2):285-299. PMID: 27980108.

Published on 9/12/2016

Nemec AA, Bush KB, Towle-Weicksel JB, Taylor BF, Schulz V, Weidhaas JB, Tuck DP, Sweasy JB. Estrogen Drives Cellular Transformation and Mutagenesis in Cells Expressing the Breast Cancer-Associated R438W DNA Polymerase Lambda Protein. Mol Cancer Res. 2016 11; 14(11):1068-1077. PMID: 27621267.

Published on 3/14/2016

Goel S, Wang Q, Watt AC, Tolaney SM, Dillon DA, Li W, Ramm S, Palmer AC, Yuzugullu H, Varadan V, Tuck D, Harris LN, Wong KK, Liu XS, Sicinski P, Winer EP, Krop IE, Zhao JJ. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. Cancer Cell. 2016 Mar 14; 29(3):255-269. PMID: 26977878.

View full list of 67 publications.